GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia
NCT ID: NCT00459212
Last Updated: 2015-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Determine the maximum tolerated dose of GTI-2040 in patients with relapsed, refractory, or high-risk acute leukemia, high-grade myelodysplastic syndromes, or refractory or blastic phase chronic myelogenous leukemia.
II. Assess the toxicity and efficacy of this drug in these patients. III. Assess plasma and intracellular pharmacokinetics of this drug in these patients.
OUTLINE: This is a multicenter, dose-escalation study.
Patients receive GTI-2040 IV continuously on days 1-4 and 15-18. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of GTI-2040 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Blood samples are collected on days 1, 4, 15, and 19 of course 1 for pharmacokinetic studies. Samples are analyzed by proteomic assay, dCTP pool measurement, and real-time polymerase chain reaction for mRNA of RRM2, RRM1, and p53R2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
GTI-2040
Given IV
pharmacological study
Correlative study
laboratory biomarker analysis
Correlative study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GTI-2040
Given IV
pharmacological study
Correlative study
laboratory biomarker analysis
Correlative study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) refractory to primary standard induction therapy
* Relapsed or refractory acute leukemia
* Chronic myelogenous leukemia (CML) in blast crisis at diagnosis OR that failed prior aggressive induction chemotherapy
* Diagnosis of 1 of the following:
* Acute leukemia secondary to preexisting hematologic condition or prior chemotherapy at diagnosis OR that failed prior aggressive induction chemotherapy
* Advanced myelodysplastic syndromes (intermediate-1 or greater)
* De novo acute leukemia (myeloid or nonmyeloid)
* Not a candidate for aggressive standard induction chemotherapy
* De novo AML or ALL (patients \> 60 years of age)
* No suspected or proven active CNS leukemia
* ECOG performance status (PS) 0-2 OR Karnofsky PS 50-100%
* Life expectancy \>= 8 weeks
* Bilirubin =\< 1.5 mg/dL
* AST and ALT \< 3 times upper limit of normal (ULN)
* Creatinine =\< 1.5 times ULN
* No HIV positivity
* Fertile patients must use effective contraception
* No history of allergic reactions attributed to other phosphorothiolated oligonucleotides
* No uncontrolled intercurrent illness including, but not limited to, any of the following:
* Ongoing, active, or poorly controlled infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* No uncontrolled intercurrent illness including, but not limited to, any of the following:
* Cardiac arrhythmia
* Poorly controlled pulmonary disease
* Psychiatric illness or social situation that would preclude study compliance
* Recovered from all prior therapies
* Prior autologous or allogeneic stem cell transplantation allowed (No active graft-vs-host disease \> grade 2)
* At least 2 weeks since prior and no concurrent cytotoxic chemotherapy
* At least 2 weeks since prior and no concurrent biologic therapy
* At least 2 weeks since any other prior investigational agent
* No other concurrent anticancer therapy, including radiotherapy or hormonal therapy
* Concurrent imatinib mesylate for CML allowed
* Not pregnant or nursing
* Negative pregancy test
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Kirschbaum
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PHI-57
Identifier Type: -
Identifier Source: secondary_id
CDR0000539257
Identifier Type: -
Identifier Source: secondary_id
NCI-2009-00206
Identifier Type: -
Identifier Source: org_study_id